The purpose of this study is to investigate the short term and long term effects of Roux-en-Y gastric bypass (RYGB) surgery on energy expenditure, gastrointestinal and appetite regulating hormone levels, and appetite sensation. We hypothesize that following RYGB surgery, metabolism will be elevated in comparison to patients who have not yet had RYGB but who are losing weight simultaneously using a low calorie diet. We further hypothesize that this higher metabolism will be associated with alterations in fasting and postmeal levels of gastrointestinal and appetite regulating hormones. Long term (1.5 years after RYGB), we hypothesize that differences in metabolism, body composition, and hormone levels will distinguish between patients who have maintained their weight loss after RYGB vs those who have regained weight.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
32
Briefly, RYGB is characterized first by creation of a small stomach pouch. The small intestine is then divided approximately 75 cm distal to the ligament of Treitz, creating a proximal intestinal limb that transports the secretions from the stomach remnant, liver, and pancreas, and a 'Roux' limb, that is attached to the new stomach pouch to drain consumed food. The distal end of the proximal limb is then reattached approximately 100 cm distal to the new stomach drainage site, creating a common channel where digestive enzymes mix with ingested food.
Patients will consume a daily diet composed of: * 4 powder diet portions (Cambridge Diets, UK) * plain yogurt (100-125g) * skim milk (1L) * a limited variety of vegetables The diet will be consumed by both groups for a 10 week period.
Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen
Copenhagen, Denmark
Hvidovre Hospital
Copenhagen, Denmark
Change in 24 hour energy expenditure
Time frame: 7 weeks, 10 weeks (short term); 1.5 years (long term)
change in fasting bile acids and lipid profile
Time frame: 7 weeks, 10 weeks (short term); 1.5 years (long term)
changes in fasting levels of leptin, adiponectin, and visfatin
Time frame: 7 weeks, 10 weeks (short term); 1.5 years (long term)
change in body composition
Time frame: 7 weeks, 10 weeks (short term); 1.5 years (long term)
Change in appetite sensation
Time frame: 7 weeks, 10 weeks (short term); 1.5 years (long term)
change in fasting and postprandial levels of GLP-1, PYY, oxyntomodulin, glucose, insulin, C peptide, GIP, ghrelin, cholecystokinin
Time frame: 7 weeks, 10 weeks (short term); 1.5 years (long term)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.